A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

Phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (amg 334) in migraine prevention: primary results of the strive trial

(2017) Peter J Goadsby et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial

(2017) Stewart Tepper et al.   LANCET NEUROLOGY

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

(2017) Thuy Vu et al.   PHARMACEUTICAL RESEARCH

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Hong Sun et al.   LANCET NEUROLOGY

The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies

(2015) Rebecca C. Burch et al.   HEADACHE

A Randomized, Placebo-Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina

(2012) B R Chaitman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes

(2011) RJ Bailey et al.   BRITISH JOURNAL OF PHARMACOLOGY

Migraine prevalence by age and sex in the United States: A life-span study

(2010) TW Victor et al.   CEPHALALGIA

Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis

(2008) C. P. Regan et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS